Importance of a multi-tiered treatment approach for intellectually and developmentally disabled patients with hidradenitis suppurativa.

Autor: Nosrati A; Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, 3411 Wayne Ave 2Nd Floor, Bronx, New York, NY, 10461, USA., Torpey ME; Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, 3411 Wayne Ave 2Nd Floor, Bronx, New York, NY, 10461, USA., Andriano TM; Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, 3411 Wayne Ave 2Nd Floor, Bronx, New York, NY, 10461, USA., Benesh G; Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, 3411 Wayne Ave 2Nd Floor, Bronx, New York, NY, 10461, USA., Babbush KM; Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, 3411 Wayne Ave 2Nd Floor, Bronx, New York, NY, 10461, USA., Hosgood HD; Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, 3411 Wayne Ave 2Nd Floor, Bronx, New York, NY, 10461, USA., Campton KL; Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, 3411 Wayne Ave 2Nd Floor, Bronx, New York, NY, 10461, USA., Cohen SR; Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, 3411 Wayne Ave 2Nd Floor, Bronx, New York, NY, 10461, USA. steven.cohen@einsteinmed.edu.
Jazyk: angličtina
Zdroj: Archives of dermatological research [Arch Dermatol Res] 2023 Aug; Vol. 315 (6), pp. 1827-1829. Date of Electronic Publication: 2023 Feb 06.
DOI: 10.1007/s00403-023-02543-3
Abstrakt: Hidradenitis suppurativa (HS) is a chronic, debilitating skin condition that is characterized by painful pustules, nodules, abscesses, and sinus tracts. The complicated and fast-evolving treatment of HS consists of a multi-tiered approach that includes, antibacterial, antihormonal, anti-inflammatory, and surgical options. Studies have demonstrated an earlier age of onset and increased prevalence of HS in patients with intellectual and developmental disability (IDD) compared to patients without IDD. To explore the use of an intensive multi-tiered HS management algorithm that requires monthly office visits, monthly intravenous therapy, and several daily treatment modalities in an HS population with IDD, we conducted an IRB-approved retrospective chart review of HS patients treated at the Albert Einstein College of Medicine-Montefiore HS Center (HSC) with diagnoses of concurrent IDD to investigate their demographic and diagnostic characteristics, as well as the spectrum of therapies employed in this cohort. A total of 22 HS patients with concomitant IDD, including trisomy 21, unspecified intellectual disability, autism spectrum disorder, and trisomy 13 were identified. Therapies utilized in this cohort for HS included topical and oral antibiotics, spironolactone, finasteride, oral contraceptive pills, infliximab, adalimumab, isotretinoin, intralesional and intramuscular triamcinolone injections, and excisional surgery. In conclusion, our findings indicate that despite the practical challenges, daily oral antibiotic regimens, anti-androgen combinations, oral retinoids, infliximab, adalimumab, and surgery collectively play important roles in treating HS patients with IDD. Our cases underscore the importance of utilizing the full range of modalities as the HS treatment algorithm continues to evolve.
(© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: